Biocon Ltd. on Tuesday said it has received approval from the U.S. health regulator for a generic anti-cancer medication.
The company has received approval from the U.S. Food and Drug Administration for Dasatinib tablets to market in strengths of 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg, Biocon said in a regulatory filing.
The approval will further strengthen the company's portfolio of vertically integrated, complex drug products, it added.
Shares of Biocon settled 4.97% higher at Rs 298.75 apiece on the BSE.
ADVERTISEMENT
Add us to your Preferences
Set as your preferred source on Google
ADVERTISEMENT
RECOMMENDED FOR YOU

Trump Names India, China, Pakistan Among 23 Major Illicit-Drug-Producing Or Transit Nations


Women Taking Ozempic Face Risks Of Unplanned Pregnancy: Study


USFDA Issues Form 483 With Eight Observations To Aurobindo's Telangana Unit


Lupin Gets USFDA Nod For Generic Risperidone Extended-Release Injectable Suspension
